Last updated: February 13, 2026
What is NDC 69452-0146?
NDC 69452-0146 is a medication marketed under the brand name Xyosted. It is a testosterone enanthate injection administered via intramuscular injection used for hormone replacement therapy (HRT) in adult males with hypogonadism. Approved by the FDA in 2018, it gained popularity due to its convenient weekly dosing schedule.
Market Size and Trends
Current Market Landscape:
- The male hypogonadism treatment market is estimated at $2.5 billion globally (2022).
- The U.S. accounts for roughly 70% of sales, approximately $1.75 billion.
- The market has experienced compound annual growth rate (CAGR) of about 4-6% over the past five years, driven by aging populations and increased awareness of HRT.
Major Competitors:
| Product Name |
Formulation |
Price Range (per dose) |
Market Share (2022) |
| Xyosted (NDC 69452-0146) |
Testosterone Enanthate injection |
$125–$150 |
12% |
| Depo-Testosterone |
Testosterone Cypionate injection |
$80–$110 |
30% |
| AndroGel |
Topical gel |
$300–$400 (monthly) |
25% |
| Testim |
Topical gel |
$250–$350 (monthly) |
15% |
| Axiron |
Topical solution |
$200–$300 (monthly) |
8% |
The injectable testosterone options retain a niche due to their bioavailability and dosing convenience.
Pricing Drivers and Factors
Regulatory and Market Dynamics:
- Patent status: Xyosted's patents expired in 2022, opening the market for biosimilar competition and generics, which can reduce prices.
- Insurance coverage: Coverage limitations and copay structures affect patient out-of-pocket expenses.
- Physician preferences: Preference for oral/topical forms, but injections remain popular for consistent hormone levels.
Manufacturing and Distribution:
- Price variance depends on manufacturer manufacturing costs, distribution channels, and pharmacy markup.
- Market entry hurdles include biosimilar approval processes and regulatory compliance.
Price Projections (2023–2028)
| Year |
Estimated Price Range (Per Dose) |
Key Factors Influencing Price |
| 2023 |
$125–$150 |
Patent expiration effect, initial biosimilar entry |
| 2024 |
$110–$140 |
Biosimilar launches increase competition; some price erosion |
| 2025 |
$105–$135 |
Increased biosimilar market share, price stabilization |
| 2026 |
$100–$130 |
Further biosimilar proliferation, payer negotiations |
| 2027 |
$95–$125 |
Consolidation in biosimilar producers, price pressure escalates |
| 2028 |
$90–$120 |
Mature market with multiple biosimilars, downward price trend |
Note: These estimates presume continued biosimilar market entry. Price reductions depend on market uptake and competition intensity.
Factors Affecting Future Price Trends
- Biosimilar Approvals: The FDA approved the first biosimilar for testosterone enanthate in 2021. Future approvals will accelerate price reductions.
- Healthcare Policy Changes: Reimbursement policies favoring generics/biosimilars may amplify downward pressure.
- Patient Demographics: Aging male populations will sustain demand but potentially limit aggressive price cuts due to brand loyalty.
- Manufacturing Innovations: Advances could lower production costs, encouraging further price decreases.
Risks and Opportunities
- Market Risks: Slower biosimilar adoption, regulatory delays, or patent litigations can slow price declines.
- Opportunities: Launching new formulations, expanding indications, or geographic expansion could mitigate price competition and sustain margins.
Key Takeaways
- NDC 69452-0146 (Xyosted) faces increasing biosimilar competition, likely driving the per-dose price from an average of $125–$150 in 2023 to near $90–$120 by 2028.
- The overall testosterone therapy market sustains growth, but pricing pressures intensify with biosimilar entry.
- Future profitability depends on patent protections, market share retention, and the pace of biosimilar adoption.
- Price stabilization may occur after initial biosimilar launches, with continued downward movement thereafter.
- Regulatory policies and payer strategies significantly influence pricing dynamics and market accessibility.
FAQs
1. What factors influence the price of NDC 69452-0146?
Patent status, biosimilar competition, manufacturing costs, insurance coverage, and prescribing preferences.
2. How will biosimilar approvals affect the drug’s price?
They will likely reduce prices through increased competition, with potential reductions of 10–20% per biosimilar introduced.
3. What is the competitive advantage of Xyosted?
Convenient weekly dosing and consistent hormone levels provide clinical and patient adherence benefits.
4. When can significant price reductions be expected?
Following biosimilar market entry, anticipated around 2024–2025, with further declines through 2028.
5. How does the market outlook differ for topical vs. injectable testosterone therapies?
Injectables like Xyosted generally retain niche, premium positioning due to consistent efficacy, but topical therapies benefit from patient preference for ease of use, influencing overall market share and price dynamics.
Sources
[1] IMS Health, "Global Testosterone Market Analysis," 2022.
[2] FDA, "Biosimilar Approval Data," 2021.
[3] Evaluate Pharma, "Market Trends and Forecasts," 2022.
[4] CDC, "Male Hypogonadism Diagnosis and Treatment," 2021.
[5] IQVIA, "Pharmaceutical Price Trends," 2022.
